There and back again: a tale of norepinephrine and drug addiction.
Fueled by anatomical, electrophysiological, and pharmacological analyses of endogenous brain reward systems, norepinephrine (NE) was identified as a key mediator of both natural and drug-induced reward in the late 1960s and early 1970s. However, reward experiments from the mid-1970s that could distinguish between the noradrenergic and dopaminergic systems resulted in the prevailing view that dopamine (DA) was the primary 'reward transmitter' (a belief holding some sway still today), thereby pushing NE into the background. Most damaging to the NE hypothesis of reward were studies demonstrating that NE receptor antagonists and NE reuptake inhibitors failed to impact drug self-administration. In recent years new tools, such as genetically engineered mice, and new experimental paradigms, such as reinstatement of drug seeking following withdrawal, have propelled NE back into the awareness of addiction researchers. Of particular interest is disulfiram, an inhibitor of the NE biosynthetic enzyme dopamine beta-hydroxylase, which has demonstrated promising efficacy in the treatment of cocaine dependence in preliminary clinical trials. The purpose of this review is to synthesize the new data linking NE to critical aspects of DA signaling and drug addiction, with a focus on psychostimulants (eg, cocaine), opiates (eg, morphine), and alcohol.
Weinshenker
David
D
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA. dweinshenker@genetics.emory.edu
Schroeder
Jason P
JP
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D000431:Ethanol / Q000494:pharmacology; D006801:Humans; D009638:Norepinephrine / Q000096:biosynthesis*; D012201:Reward; D013375:Substance Withdrawal Syndrome / Q000378:metabolism / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology
D000701:Analgesics, Opioid; D000697:Central Nervous System Stimulants; D000431:Ethanol; D004298:Dopamine; D009638:Norepinephrine